CuDox-TSL

CuDox-TSL (Copper ion mediated Doxorubicin loading–Temperature Sensitive Liposomes) is a research-stage, heat-activatable nanoparticle drug delivery formulation developed by researchers at the University of California, Davis and Stanford University. It consists of a pH-sensitive complex between the chemotherapeutic agent doxorubicin and copper ions, encapsulated within lysolipid-containing temperature-sensitive liposomes. The copper-doxorubicin (CuDox) complex stabilizes the liposome at physiological pH, minimizing systemic exposure and associated cardiotoxicity of free doxorubicin. Localized drug release is triggered by mild hyperthermia (~42°C) induced via focused ultrasound at the tumor site. CuDox-TSL has been investigated in preclinical models of breast cancer and melanoma, often in combination with immunotherapies like CpG oligonucleotides and anti-PD-1 antibodies to stimulate local and systemic (abscopal) anti-tumor immune responses.

Other names

Copper ion mediated Doxorubicin loading–Temperature Sensitive Liposomescopper-doxorubicin temperature-sensitive liposomes